MedTrace Logo

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

NCT01765790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-05-05

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).

Conditions

  • Metastatic Adenocarcinoma of the Colon or Rectum
  • Malignant Solid Tumors

Interventions

BIOLOGICAL

Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

* Dosing every 2 weeks * Intravenous injection

BIOLOGICAL

Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

* Dosing weekly * Intravenous injection

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-14
Primary Completion
2016-07-28
Completion
2016-07-28

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01765790 on ClinicalTrials.gov